# Evaluation of 123-I Iodobenzovesamicol (IBVM) and SPECT Imaging of Healthy Subjects and Patients With Alzheimer Disease

> **NCT00480701** · PHASE2 · COMPLETED · sponsor: **Institute for Neurodegenerative Disorders** · enrollment: 26 (actual)

## Conditions studied

- Alzheimer Disease
- Parkinson Disease

## Interventions

- **DRUG:** [123I]-IBVM

## Key facts

- **NCT ID:** NCT00480701
- **Lead sponsor:** Institute for Neurodegenerative Disorders
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-02
- **Primary completion:** 2011-10
- **Final completion:** 2011-10
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2014-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00480701

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00480701, "Evaluation of 123-I Iodobenzovesamicol (IBVM) and SPECT Imaging of Healthy Subjects and Patients With Alzheimer Disease". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00480701. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*